title: Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition.
abstract: BACKGROUND
  Patients with atherosclerotic renovascular disease (ARVD) are almost invariably treated by revascularization. However, the long-term outcomes of this approach on survival and progression to renal failure have not been investigated and have not been compared with that of a purely medical treatment. The aim of this observational study was to investigate factors affecting long-term (over 5 years) outcome, survival and renal function of patients with ARVD treated invasively or medically.
  
  
  METHODS
  ARVD was demonstrated angiographically in 195 patients who were consecutively enrolled into a follow-up study. Patient age was 65.6+/-11.2 years, serum creatinine was 1.74+/-1.22 mg/dl and renal artery lumen narrowing was 73.5+/-17.5%. A revascularization was performed in 136 patients, whereas 54 subjects having comparable characteristics were maintained on a medical treatment throughout the study; five patients were lost during follow-up.
  
  
  RESULTS
  The main follow-up was 54.4+/-40.4 months. The assessment of cardiovascular survival and renal survival at the end of follow-up revealed 46 cardiovascular deaths, 20 patients with end-stage renal disease (ESRD) and 41 patients with an increase in serum creatinine of over one-third. The multivariate analysis showed that renal revascularization did not affect mortality or renal survival compared with medical treatment. Revascularization produced slightly lower increases in serum creatinine and a better control of blood pressure. A longer survival was associated with the use of angiotensin-converting enzyme inhibitors (ACEIs) (P = 0.002) in both revascularized and medically treated patients. The only significant predictor of ESRD was an abnormal baseline serum creatinine.
  
  
  CONCLUSIONS
  On long-term follow-up, ARVD was associated with a poor prognosis due to a high cardiovascular mortality and a high rate of ESRD. In our non-randomized study, revascularization was not a major advantage over medical treatment in terms of mortality or renal survival. The use of ACEIs was associated with improved survival.
authors.affiliation: Unità Operativa Nefrologia e Dialisi, Policlinico Monteluce, Università di Perugia, Italy. atlosito@tin.it
authors.forename: Attilio
authors.initials: A
authors.lastname: Losito
authors.forename: Rosa
authors.initials: R
authors.lastname: Errico
authors.forename: Paola
authors.initials: P
authors.lastname: Santirosi
authors.forename: Tommaso
authors.initials: T
authors.lastname: Lupattelli
authors.forename: Giovanni Battista
authors.initials: GB
authors.lastname: Scalera
authors.forename: Luciano
authors.initials: L
authors.lastname: Lupattelli
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003404:Creatinine / Q000097:blood; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D008297:Male; D012078:Renal Artery Obstruction / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D015996:Survival Rate
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D003404:Creatinine